Suppression of STING associated with LKB1 loss in KRAS-driven lung cancer

KRAS-driven lung cancers frequently inactivate TP53 and/or STK11/LKB1, defining tumor subclasses with emerging clinical relevance. Specifically, KRAS-LKB1 (KL) mutant lung cancers are particularly aggressive, lack PD-L1, and respond poorly to immune checkpoint blockade (ICB). The mechanistic basis f...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Cancer Discov
Main Authors: Kitajima, Shunsuke, Ivanova, Elena, Guo, Sujuan, Yoshida, Ryohei, Campisi, Marco, Sundararaman, Shriram K., Tange, Shoichiro, Mitsuishi, Yoichiro, Thai, Tran C., Masuda, Sayuri, Piel, Brandon P., Sholl, Lynette M., Kirschmeier, Paul T., Paweletz, Cloud P., Watanabe, Hideo, Yajima, Mamiko, Barbie, David A.
Format: Artigo
Sprog:Inglês
Udgivet: 2018
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6328329/
https://ncbi.nlm.nih.gov/pubmed/30297358
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-18-0689
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker